Genital Herpes in 8MM is expected to witness a major change in the study period 2019-2032

The Genital Herpes market report provides emerging drugs, Genital Herpes market share of the individual cancer types, current and forecasted Genital Herpes market size from 2019 to 2032 segmented by eight major markets. The Report also covers current Genital Herpes unmet medical needs to curate best of the opportunities and assesses underlying potential of the market. The genital herpes market is expected to grow significantly owing to the increase in diagnosed genital herpes cases per year, awareness, and anticipated launch of emerging therapies by key players such as AiCuris, United BioPharma, Heidelberg ImmunoTherapeutics, Genocea Biosciences, GlaxoSmithKline, and others.

Key takeaways from the Genital Herpes Market Research Report
• As per DelveInsight analysis, the genital herpes market size in the 7MM + China was approximately USD 1,125 million in 2021.
• According to DelveInsight, the Genital Herpes in 8MM is expected to witness a major change in the study period 2019-2032.
• Leading Genital Herpes companies such as AiCuris, United BioPharma, Heidelberg ImmunoTherapeutics, Genocea Biosciences, Agenus, Fresh Tracks Therapeutics, Sanofi, GlaxoSmithKline, and others are developing novel genital herpes drugs that can be available in the genital herpes market in the coming years.
• The promising Genital Herpes therapies in the pipeline include AIC-316 (pritelivir), UB-621, HDIT101, SIMPLIRIX (GSK208141), GEN-003, HerpV (AG-707), VCL-HB01, SP-0148, and others.

Recent Developmental Activities in the Genital Herpes Market
• In August 2022, Rational Vaccines Inc. announced the start of an observational clinical trial to determine the baseline characteristics of patients with recurrent symptomatic herpes simplex virus type 2 infection (HSV-2).
• Pritelivir is a highly potent inhibitor of HSV replication. It belongs to a new chemical class and acts via a novel mechanism of action (inhibition of the viral helicase-primase enzyme complex). In contrast to currently used nucleoside analogues, Pritelivir does not require activation by viral enzymes and can thus protect uninfected cells. Pritelivir is being developed for the treatment of acyclovir-resistant and dual-resistant (resistant to acyclovir and intolerant or resistant to foscarnet) infections in immune-compromised patients.
• UB 621 is a novel, fully human monoclonal antibody that interferes with HSV infection by binding specifically to HSV envelope glycoprotein D (gD). It has been shown in vitro to block HSV infections of both wild type and acyclovir-resistant viral strains with over hundreds-fold higher potency. Pre-clinical and early clinical data show that UB-621 has the potential to suppress recurrence of genital herpes. The drug is in phase II stage of development for the treatment of Genital Herpes.

Discover which therapies are expected to grab the major Genital Herpes Market Share Report @ https://www.delveinsight.com/sample-request/genital-herpes-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Genital Herpes Overview

Genital herpes is a chronic sexually transmitted infection (STI) characterized by genital blisters and open sores (lesions). Among the genital herpes causes, two types of herpes simplex virus (HSV), HSV-1 and HSV-2, play an important role. The virus becomes active for a short period before going dormant; when active, it travels to the surface of the infected area (skin or mucous membrane) and replicates itself. This is referred to as "shedding" because the viruses can rub off and spread to another person at this stage. Genital herpes can be asymptomatic or have mild symptoms that go unrecognized. When symptoms occur, genital herpes is characterized by one or more genital or anal blisters or ulcers.

Additionally, symptoms of a new infection often include fever, body aches, and swollen lymph nodes. After an initial episode, which can be severe, symptoms may recur. Genital herpes caused by HSV-1 typically does not recur frequently. With HSV-2, recurrent symptoms are common; however, recurrences are often less severe than the first episode and tend to decrease over time.

Genital Herpes Epidemiology Segmentation in the 7MM
• Genital Herpes Prevalent HSV infected cases
• Genital Herpes Symptomatic cases per year
• Genital Herpes cases, by gender
• Genital Herpes Diagnosed cases per year
• Total Genital Herpes recurrent cases
• Genital Herpes Treated patient pool

Download the report to understand which factors driving genital herpes epidemiology trends are @ https://www.delveinsight.com/sample-request/genital-herpes-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Genital Herpes Treatment Market

Genital herpes treatment is assigned to patients based on the type of HSV that caused the infection and the number of episodes of infection. Different regimens are recommended for the first clinical episode, episodic therapy and suppressive therapy; different therapeutic regimens are recommended for HSV-1 and HSV-2. There are also specific guidelines for managing complications associated with genital herpes, such as HIV infection, antiviral-resistant HSV infection, herpes during pregnancy, and neonatal pregnancy. Although genital herpes has no known cure, but daily use of antiviral medications can prevent or shorten outbreaks. Antiviral medications can also reduce the likelihood of it spreading to others. For genital herpes treatment, effective oral antiviral medications are available. These genital herpes medications provide clinical benefits but do not cure the disease. These medications can be used for either short-term or long-term suppressive therapy.

Genital Herpes Pipeline Therapies and Key Companies
• AIC-316 (pritelivir): AiCuris
• UB-621: United BioPharma
• HDIT101: Heidelberg ImmunoTherapeutics
• SIMPLIRIX (GSK208141): GlaxoSmithKline
• GEN-003: Genocea Biosciences
• HerpV (AG-707): Agenus
• VCL-HB01: Fresh Tracks Therapeutics
• SP-0148: Sanofi

Genital Herpes Market Dynamics

Genital herpes is a common sexually transmitted disease. As the population of various geographies grows, so does the prevalence of health issues worldwide. As a result of the increasing prevalence of diseases, the genital herpes market will increase in the coming years. In addition to a rapidly growing population, the increased awareness and diagnosis would present appealing potential opportunities for the genital herpes market. However, there are significant unmet needs in the genital herpes market. Although genital herpes is an STI, it has a significant impact on patients' mental and social health and sexual health. Furthermore, the diagnostic tests for genital herpes are inaccurate. Most HSV-infected people are asymptomatic or have very mild symptoms that go unnoticed or are misdiagnosed as another skin condition.

Learn more about the FDA-approved drugs for Genital Herpes Treatment @ https://www.delveinsight.com/report-store/genital-herpes-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Genital Herpes Market Research Report
• Coverage- 7MM
• Genital Herpes Companies- AiCuris, United BioPharma, Heidelberg ImmunoTherapeutics, Genocea Biosciences, Agenus, Fresh Tracks Therapeutics, Sanofi, GlaxoSmithKline, and others
• Genital Herpes Pipeline therapies- 316 (pritelivir), UB-621, HDIT101, SIMPLIRIX (GSK208141), GEN-003, HerpV (AG-707), VCL-HB01, SP-0148, and others
• Unmet Needs, KOL's views, Analyst's views, Genital Herpes Market Access and Reimbursement

Table of Content
1. Key Insights
2. Genital Herpes Report Introduction
3. Genital Herpes Market Overview at a Glance
4. Executive Summary of Genital Herpes
5. Epidemiology and Market Methodology
6. Disease Background and Overview
7. Genital Herpes Treatment
8. Genital Herpes Epidemiology and Patient Population
9. Patient Journey of Genital Herpes
10. Key Endpoints in Genital Herpes Clinical Trials
11. Genital Herpes Emerging Therapies
12. Genital Herpes: 8 Major Market Analysis
13. Genital Herpes Market Access and Reimbursement
14. KOL Views
15. SWOT Analysis
16. Genital Herpes Unmet Needs
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

Discover more about drugs for genital herpes treatment in development & Clinical Trials @ https://www.delveinsight.com/report-store/genital-herpes-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

This release was published on openPR.